Skip to main content

Security report for xyphosinc.com

Xyphos Inc · Healthcare · United States

Medium risk. 7 critical or high findings in Security headers, GDPR outside view and 1 other check.

Security score

65/100

Risk levelMedium

0–100, higher is better. How it is calculated

Xyphos Biosciences, Inc. is a small biotechnology company specializing in the development of flexible and adaptable immune cell therapies aimed at revolutionizing cancer care. The company operates as a subsidiary of Astellas Pharma Inc., leveraging its parent company's resources and market presence. The website clearly targets cancer patients, healthcare professionals, investors, and potential employees, showcasing innovation in next-generation cancer immunotherapy. The business model focuses on research and development of controllable immune therapies with a strong emphasis on safety and efficacy. Technically, the website is built on WordPress and employs modern JavaScript libraries such as jQuery, Slick Carousel, and FancyApps UI. Hosting is provided by GoDaddy, and the site uses HTTPS with a good SSL configuration. Performance is moderate with good mobile optimization and basic accessibility features. SEO is well addressed with proper meta tags and structured data. However, there is room for improvement in accessibility and performance optimization. From a security perspective, the site benefits from HTTPS and lacks exposed sensitive data. However, it does not implement DNSSEC, nor does it use common security headers like Content-Security-Policy or HSTS. There are no published security policies or incident response contacts, and privacy compliance is weak due to the absence of privacy and cookie policies. Google Analytics is used for tracking, indicating moderate user tracking without clear privacy disclosures. Overall, the website presents a professional and credible business front with strong ties to a reputable parent company. The main risks lie in privacy compliance and security hardening. Strategic recommendations include implementing comprehensive privacy and cookie policies, enabling DNSSEC, adding security headers, and publishing security and incident response policies to enhance trust and compliance.

Scanned

NIS2 and GDPR posture

GDPR outside view
35/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

7 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

  2. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      No Cookie Policy found

      GDPR requires clear information about cookie usage

      What to do: Add a dedicated cookie policy explaining cookie usage and purposes

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

    • High

      Third-party services without privacy policy

      Detected services: Google Analytics, LinkedIn, Google APIs

      What to do: Document all third-party data sharing in your privacy policy

Need hands-on remediation? Email guard@offseq.com

Keep watching xyphosinc.com

This scan found 23 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
47
Security headers
60
Email security
70
DNS health
75
Network security
100
GDPR outside view
35
Average
65

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Xyphos Biosciences positions itself as an innovator in the cancer immunotherapy sector, focusing on flexible immune cell therapies. Its affiliation with Astellas Pharma provides competitive advantages including financial backing and market access. The business model is research-driven with potential revenue streams from partnerships, licensing, and eventual product commercialization. The target customers include healthcare providers and patients seeking advanced cancer treatments. Growth indicators include active recruitment and pipeline visibility through parent company links. The partnership ecosystem is strong, leveraging Astellas' global presence. Operationally, the company maintains a focused digital presence with professional branding and clear messaging aligned with its mission.

Security posture

The current security maturity level is moderate. HTTPS is enforced, and no sensitive data leaks were detected. However, the absence of DNSSEC and security headers exposes the site to potential DNS spoofing and clickjacking risks. The lack of published security policies and incident response contacts indicates limited transparency and preparedness. Compliance gaps exist in privacy and cookie policy disclosures, which may affect GDPR and other regulatory adherence. The use of third-party scripts like Google Analytics introduces tracking without clear user consent mechanisms. Overall, the security culture appears basic, with opportunities to enhance governance and technical controls.

Recommendations

  1. Implement a comprehensive privacy policy and cookie consent mechanism to improve GDPR compliance.
  2. Enable DNSSEC on the domain to strengthen DNS security and prevent spoofing.
  3. Add essential security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security.
  4. Publish clear security and incident response policies including dedicated contact channels for security issues.
  5. Conduct regular security audits of third-party scripts and update dependencies to mitigate vulnerabilities.

Contact details published on the site

Addresses
Legal name
Xyphos Biosciences, Inc.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Xyphos Inc
Description
At Xyphos, we’re working to deliver flexible and adaptable cancer therapies with the potential to revolutionize cancer care.
Key services
Flexible and controllable immune cell therapy development, Cancer immunotherapy research and innovation
Content quality
good
Branding
consistent

Technology

Stack
jQuery, jQuery UI, Slick Carousel, FancyApps UI, Google Analytics, Modernizr
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
65/100
Good practices seen
  • HTTPS enabled
  • No exposed sensitive data in HTML
  • Use of security-related meta tags (robots)

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
poor

Advertising

Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
moderate

Key observations

  1. Website is professionally designed and content-rich focused on cancer immunotherapy
  2. No privacy or cookie policies found, indicating compliance gaps
  3. No explicit security or incident response policies published
  4. Use of modern JavaScript libraries and WordPress CMS
  5. Strong affiliation with parent company Astellas Pharma
  6. No suspicious or malicious indicators detected
Technical notes

Notes

The website infrastructure is based on WordPress CMS hosted by GoDaddy, utilizing common JavaScript libraries for UI and interactivity. The site loads external resources from reputable CDNs, ensuring availability and performance. While the site is mobile optimized and SEO friendly, accessibility features are basic and could be improved. Performance is moderate, with potential gains from optimizing scripts and images. The absence of advanced frameworks or platforms suggests a straightforward technical stack with manageable complexity. Technical risks include reliance on third-party scripts without visible integrity checks and missing DNSSEC configuration.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with xyphosinc.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review xyphosinc.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.